Among all countries worldwide those in sub-Saharan Africa have the highest rates of HIV. The countries with the highest rates of HIV include Eswatini, Lesotho, and South Africa. In 2023, Eswatini had the highest prevalence of HIV with a rate of around 25 percent. Other countries, such as Zimbabwe, have significantly decreased their HIV prevalence. Community-based HIV services are considered crucial to the prevention and treatment of HIV. HIV Worldwide The human immunodeficiency virus (HIV) is a viral infection that is transmitted via exposure to infected semen, blood, vaginal and anal fluids and breast milk. HIV destroys the human immune system, rendering the host unable to fight off secondary infections. Globally, the number of people living with HIV has generally increased over the past two decades. However, the number of HIV-related deaths has decreased significantly in recent years. Despite being a serious illness that affects millions of people, medication exists that effectively manages the progression of the virus in the body. These medications are called antiretroviral drugs. HIV Treatment Generally, global access to antiretroviral treatment has increased in recent years. However, despite being available worldwide, not all adults have access to antiretroviral drugs. Europe and North America have the highest rates of antiretroviral use among people living with HIV. There are many different antiretroviral drugs available on the market. As of 2023, Biktarvy, an antiretroviral marketed by Gilead, was the leading HIV treatment based on revenue.

The total number of people globally living with HIV has increased from 27.2 million people in 2000 to 39.9 million people in 2023. However, the total number of new HIV infections has decreased from 2.8 million in 2000 to 1.3 million in 2023. It has become easier for those infected with HIV to live longer lives. Death rates for HIV-positive people are decreasing, mostly due to antiretroviral drugs that have turned the infection into a chronic disease. Nevertheless, those with HIV are at a higher risk for conditions such as liver disease, heart disease, and cancer. Medication for HIV has become more widespread and has made HIV a more manageable condition. However, medicine is not widely accessible in the developing world and treatment is still lacking. In Eswatini, around 26 percent of all people between 15 and 49 years are living with HIV, while the percentage is around 18 in South Africa. HIV infections are still especially widespread in Eastern and Southern Africa with 20.8 million people living with the condition in 2023. In the same year, there were around 2.3 million people in Latin America living with HIV.

In 2023, some 0.7 percent of the total global adult population aged between 15 and 49 years was infected with HIV. This statistic reflects the HIV prevalence among the global adult population from 1990 to 2023.

This statistic describes some of the key figures on the global HIV/AIDS epidemic as of 2023. For 2023, it was estimated that there were a total of 39.9 million people living with HIV/AIDS around the world. Around 30.7 million of these people had access to antiretroviral therapy treatment.

This dataset provides estimates for Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome (HIV/AIDS) spending for 188 countries for 2000 to 2015. Data is taken from the Institute for Health Metrics and Evaluation (IHME) and the Global Health Data Exchange.

In 2022, it was estimated that around 16.4 percent of Botswana's population aged 15-49 years was infected with HIV. This statistic shows the 20 countries with the highest prevalence of HIV worldwide as of 2022.

To control and ultimately end the HIV/AIDS epidemic, we must sustain and expand our collective gains. Led by our strategic vision, PEPFAR 3.0 – Controlling the Epidemic: Delivering on the Promise of an AIDS-free Generation, the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) is collecting and using data in the most granular manner (disaggregated by sex, age, and at the site level) to do the right things, in the right places, and right now within the highest HIV-burdened populations and geographic locations. This data asset has one Excel data file containing information on quantities, cost and procurement information for HIV rapid test kits. No human subjects’ information is included in this data.

Global Prevalence of HIV by Country, 2023 Discover more data with ReportLinker!

In 2023, in South Africa, there were around 2.7 HIV newly infected persons per every 1,000 inhabitants. This statistic depicts the countries with the highest incidence rates of new HIV infections worldwide as of 2023.

Global Incidence of HIV Among People Aged 50+ by Country, 2023 Discover more data with ReportLinker!

Mexico MX: Prevalence of HIV: Male: % Aged 15-24 data was reported at 0.200 % in 2017. This stayed constant from the previous number of 0.200 % for 2016. Mexico MX: Prevalence of HIV: Male: % Aged 15-24 data is updated yearly, averaging 0.200 % from Dec 1990 (Median) to 2017, with 28 observations. The data reached an all-time high of 0.200 % in 2017 and a record low of 0.100 % in 2009. Mexico MX: Prevalence of HIV: Male: % Aged 15-24 data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s Mexico – Table MX.World Bank.WDI: Health Statistics. Prevalence of HIV, male is the percentage of males who are infected with HIV. Youth rates are as a percentage of the relevant age group.; ; UNAIDS estimates.; Weighted average; In many developing countries most new infections occur in young adults, with young women being especially vulnerable.

Egypt EG: Incidence of HIV: per 1,000 Uninfected Population data was reported at 0.050 Ratio in 2022. This records an increase from the previous number of 0.040 Ratio for 2021. Egypt EG: Incidence of HIV: per 1,000 Uninfected Population data is updated yearly, averaging 0.010 Ratio from Dec 1990 (Median) to 2022, with 33 observations. The data reached an all-time high of 0.050 Ratio in 2022 and a record low of 0.010 Ratio in 2011. Egypt EG: Incidence of HIV: per 1,000 Uninfected Population data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s Egypt – Table EG.World Bank.WDI: Social: Health Statistics. Number of new HIV infections among uninfected populations expressed per 1,000 uninfected population in the year before the period.;UNAIDS estimates.;Weighted average;This is the Sustainable Development Goal indicator 3.3.1 [https://unstats.un.org/sdgs/metadata/].

Cameroon CM: Incidence of HIV: % of Uninfected Population Aged 15-49 data was reported at 0.210 % in 2017. This records a decrease from the previous number of 0.220 % for 2016. Cameroon CM: Incidence of HIV: % of Uninfected Population Aged 15-49 data is updated yearly, averaging 0.430 % from Dec 1990 (Median) to 2017, with 28 observations. The data reached an all-time high of 0.720 % in 1998 and a record low of 0.210 % in 2017. Cameroon CM: Incidence of HIV: % of Uninfected Population Aged 15-49 data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s Cameroon – Table CM.World Bank.WDI: Social: Health Statistics. Number of new HIV infections among uninfected populations ages 15-49 expressed per 100 uninfected population in the year before the period.; ; UNAIDS estimates.; Weighted average;

Norway NO: Incidence of HIV: per 1,000 Uninfected Population data was reported at 0.010 Ratio in 2021. This records a decrease from the previous number of 0.020 Ratio for 2020. Norway NO: Incidence of HIV: per 1,000 Uninfected Population data is updated yearly, averaging 0.030 Ratio from Dec 1990 (Median) to 2021, with 32 observations. The data reached an all-time high of 0.040 Ratio in 2015 and a record low of 0.010 Ratio in 2021. Norway NO: Incidence of HIV: per 1,000 Uninfected Population data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s Norway – Table NO.World Bank.WDI: Social: Health Statistics. Number of new HIV infections among uninfected populations expressed per 1,000 uninfected population in the year before the period.;UNAIDS estimates.;Weighted average;This is the Sustainable Development Goal indicator 3.3.1 [https://unstats.un.org/sdgs/metadata/].

Lebanon LB: Incidence of HIV: per 1,000 Uninfected Population data was reported at 0.030 Ratio in 2021. This stayed constant from the previous number of 0.030 Ratio for 2020. Lebanon LB: Incidence of HIV: per 1,000 Uninfected Population data is updated yearly, averaging 0.030 Ratio from Dec 1990 (Median) to 2021, with 32 observations. The data reached an all-time high of 0.040 Ratio in 2018 and a record low of 0.010 Ratio in 1991. Lebanon LB: Incidence of HIV: per 1,000 Uninfected Population data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s Lebanon – Table LB.World Bank.WDI: Social: Health Statistics. Number of new HIV infections among uninfected populations expressed per 1,000 uninfected population in the year before the period.;UNAIDS estimates.;Weighted average;This is the Sustainable Development Goal indicator 3.3.1 [https://unstats.un.org/sdgs/metadata/].

According to Cognitive Market Research, the global HIV Self Test Kit market size will be USD 6621.5 million in 2024. It will expand at a compound annual growth rate (CAGR) of 3.20% from 2024 to 2031. North America held the major market share for more than 40% of the global revenue with a market size of USD 2648.60 million in 2024 and will rise at the compound annual growth rate (CAGR) of 1.4% from the year 2024 to 2031. Europe accounted for a market share of over 30% of the global revenue with a market size of USD 1986.45 million. Asia Pacific held a market share of around 23% of the global revenue with a market size of USD 1522.95 million in 2024 and will rise at the compound annual growth rate (CAGR) of 5.2% from the year 2024 to 2031. Latin America had a market share of more than 5% of the global revenue with a market size of USD 331.08 million in 2024 and will rise at the compound annual growth rate (CAGR) of 2.6% from the year 2024 to 2031. Middle East and Africa had a market share of around 2% of the global revenue and was estimated at a market size of USD 132.43 million in 2024 and will rise at the compound annual growth rate (CAGR) of 2.9% from the year 2024 to 2031. The fluorescent chromatography category is the fastest growing segment of the HIV Self Test Kit industry Market Dynamics of HIV Self Test Kit Market Key Drivers for HIV Self Test Kit Market Advancements in Test Kit Technology and Accuracy to Boost Market Growth Technological advancements in HIV self-test kits, enhancing accuracy, ease of use, and rapid results, are key drivers of market growth. Innovations like oral fluid-based and finger-prick test kits, which are minimally invasive and provide results within minutes, have increased the appeal and accessibility of self-testing. Improved sensitivity and specificity in these kits ensure reliable results, fostering user confidence and market demand. Additionally, user-friendly designs and instructions make it easy for individuals to administer tests without medical supervision. These advancements are particularly valuable in remote or underserved areas where access to healthcare is limited. The development of more accurate, faster, and simpler HIV self-test kits has made them a preferred choice, bolstering the growth of the HIV self-test kit market. Rising Awareness and Government Initiatives for HIV Testing to Drive Market Growth The growing awareness about HIV and the benefits of early diagnosis is a significant driver for the HIV self-test kit market. Governments and health organizations worldwide, especially in high-prevalence regions, are actively promoting self-testing to improve access to HIV diagnostics, reduce stigma, and encourage individuals to test without visiting clinics. Campaigns and programs by organizations like UNAIDS and WHO have highlighted self-testing as a safe and private method, promoting its adoption among high-risk populations. These initiatives help increase awareness and accessibility, reducing barriers such as cost, fear of discrimination, and confidentiality concerns. As a result, HIV self-test kits are gaining acceptance as an essential tool in public health, driving market growth. Restraint Factor for the HIV Self Test Kit Market Limited Awareness and Social Stigma Will Limit Market Growth In many regions, particularly in conservative societies, HIV remains a highly stigmatized condition, leading to reluctance to test and discuss HIV openly. This stigma creates barriers to purchasing self-test kits, as individuals may fear judgment or discrimination. Additionally, inadequate awareness campaigns about HIV self-testing reduce the public's understanding of the convenience, privacy, and accessibility it offers. Without effective education on the importance of early testing and the safety of self-testing methods, people may continue to avoid HIV testing, impacting the market's potential growth. Expanding acceptance and understanding of self-testing requires cultural and policy shifts, making it a challenging restraint to overcome in regions where stigma is deeply entrenched. Impact of Covid-19 on the HIV Self Test Kit Market COVID-19 significantly accelerated demand in the HIV self-test kit market, as lockdowns, healthcare restrictions, and concerns over exposure led individuals to seek private, at-home testing options. Reduced access to in-person healthcare facilities during the pandemic made self-testing an essential tool for maintaining HIV diagnosis rates while mini...

Snapshot img

HIV Drugs Market Size 2024-2028

The hiv drugs market size is forecast to increase by USD 9.99 billion at a CAGR of 5.02% between 2023 and 2028.

The market is experiencing significant growth due to several key factors. The increasing prevalence of HIV AIDS worldwide continues to drive market expansion. According to the World Health Organization, there were approximately 38 million people living with HIV in 2019. Moreover, expanding access to HIV treatment is another major growth factor. With advancements in HIV treatment, more individuals are able to access life-saving medications. However, drug resistance among individuals poses a significant challenge to the market. As HIV strains become resistant to current treatments, the development of new and effective drugs is crucial. This report provides a comprehensive analysis of these trends and challenges, offering insights into the future growth prospects of the market.

What will be the Size of the HIV Drugs Market During the Forecast Period?

Request Free SampleThe market encompasses a range of pharmaceutical products designed to manage and suppress the viral infection caused by Human Immunodeficiency Virus (HIV). This market has experienced significant growth due to the increasing prevalence of HIV and the ongoing development of new, more effective medications. Notable classes of HIV drugs include those containing CD4 modulators, such as Atripla, Complera, Prezcobix, Stribild, Genvoya, Odefsey, Symtuza, Triumeq, Descovy, Dovato, Emtriva, Epivir, and Epzicom. New product launches continue to drive market expansion, with companies investing in research and development to improve treatment outcomes and patient compliance. The healthcare products industry plays a crucial role In the import and export of HIV medications, ensuring access to these essential treatments for patients worldwide.HIV testing procedures remain a critical aspect of disease management and prevention efforts, further fueling demand for HIV medications withIn the market.

How is this HIV Drugs Industry segmented and which is the largest segment?

The hiv drugs industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments. Distribution ChannelOfflineOnlineTherapyCombination HIV medicinesIntegrase inhibitorsNon-nucleoside reverse transcriptase inhibitorsOthersGeographyNorth AmericaCanadaUSEuropeGermanyUKAsiaChinaRest of World (ROW)

By Distribution Channel Insights

The offline segment is estimated to witness significant growth during the forecast period.

Offline distribution channels, including pharmacies, drugstores, hospitals, and clinics, remain a significant segment In the market. Pharmacies and drugstores serve as crucial points of sale for HIV medications, particularly antiretroviral therapy (ART), which is essential for managing HIV/AIDS. The offline distribution segment caters to various patient populations, including those in regions with limited internet access or who prefer face-to-face interactions with healthcare professionals. Key HIV drugs, such as Atripla, Complera, Prezcobix, Stribild, Genvoya, Odefsey, Symtuza, Triumeq, Descovy, Dovato, Emtriva, Epivir, Epzicom, Truvada, Biktavir, Edurant, Aptivus, Kaletra, Lexiva, Norvir, Viracept, Selzentry, Fuzeon, Rukobia, Isentress, Tivicay, Apretude, and Juluca, are distributed offline through these channels.The offline distribution segment's growth is influenced by factors like the prevalence of HIV, testing procedures, and the availability of various HIV medications. Import and export regulations, as well as the increasing demand for healthcare products, further impact this market.

Get a glance at the HIV Drugs Industry report of share of various segments Request Free Sample

The Offline segment was valued at USD 25.82 billion in 2018 and showed a gradual increase during the forecast period.

Regional Analysis

North America is estimated to contribute 49% to the growth of the global market during the forecast period.

Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

For more insights on the market share of various regions, Request Free Sample

The North American the market has experienced substantial growth due to advancements in medical research, enhanced healthcare infrastructure, and heightened awareness about HIV/AIDS. With a significant patient population and established healthcare systems In the United States, Canada, and Mexico, North America is a leading market for HIV drugs. Key trends include the development of combination HIV medicines, such as Atripla, Complera, Prezcobix, Stribild, Genvoya, Odefsey, Symtuza, Triumeq, Descovy, Dovato, Emtriva, Epivir, Epzicom, Truvada

In 2023, some 1.1 percent of Thailand's population aged between 15 and 49 years was infected with HIV. This statistic describes the HIV prevalence among the adult population of select countries worldwide as of 2023.

Global Women's Share of Population Aged 15+ Living with HIV by Country, 2023 Discover more data with ReportLinker!

Snapshot img

Point Of Care (Poc) Hiv Testing Market Size 2024-2028

The point of care (poc) hiv testing market size is forecast to increase by USD 329.8 million at a CAGR of 3.2% between 2023 and 2028.

The market is witnessing significant growth due to several key factors. The increasing prevalence of HIV/AIDS worldwide continues to drive market demand, as early and accurate diagnosis is crucial for effective treatment and management of the disease. Additionally, rising awareness programs for HIV testing, particularly in developing and underdeveloped nations, are expanding access to testing services and boosting market growth. Limited healthcare infrastructure In these regions necessitates the use of PoC HIV testing devices, which offer rapid results and ease of use. These trends are expected to continue shaping the market dynamics In the coming years.

What will be the Size of the Point Of Care (Poc) Hiv Testing Market During the Forecast Period?

Request Free Sample

The market encompasses diagnostic devices and kits designed for rapid HIV testing at patient locations outside of centralized laboratories. With the global HIV/AIDS prevalence rate continuing to rise, there is a growing demand for convenient and quick HIV testing solutions. POC HIV testing is particularly relevant to scenarios involving blood transfusions and donations, as well as in healthcare institutions and home healthcare settings. These tests provide immediate results, enabling timely treatment decisions and improved patient outcomes. The market is also influenced by the increasing prevalence of chronic diseases such as HIV, tuberculosis, and influenza, which necessitate early detection and personalized medicine.
Additionally, demographic trends, including an aging population and increased patient autonomy, are driving the growth of the POC HIV testing market. Despite the advantages, challenges such as turnaround time and cost remain, necessitating ongoing innovation and competition withIn the market.

How is this Point Of Care (Poc) Hiv Testing Industry segmented and which is the largest segment?

The point of care (poc) hiv testing industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD million' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

Product

  POC HIV testing equipment
  POC HIV testing reagents


End-user

  Diagnostic labs
  Hospitals and clinics
  Others


Geography

  North America

    US


  Europe

    Germany
    UK
    France


  Asia

    China


  Rest of World (ROW)

By Product Insights

The poc hiv testing equipment segment is estimated to witness significant growth during the forecast period.

POC HIV testing equipment refers to devices and tools used for HIV testing at or near the patient's care location. This includes rapid HIV test kits, POC HIV viral load testing systems, and POC CD4 count devices. POC testing plays a crucial role in expanding HIV testing access, improving early diagnosis, and increasing linkage to care, particularly in underdeveloped nations and community-based programs. Early diagnosis and swift treatment initiation are essential strategies to combat HIV spread. POC HIV testing equipment advances diagnostics and clinical services, enabling healthcare institutions to provide ART supplies and minimize turnaround time. UNAIDS reports that HIV-related mortality and new infections can be reduced through widespread testing, pre- and post-test counselling, and timely interventions.

Key dynamics driving the POC HIV testing market include chronic diseases, lifestyle-borne diseases, real-time diagnosis, miniaturization of devices, and advanced technologies like biosensors and nanotechnology. Cost-effective, rapid testing is essential for patient management of target diseases, including blood-related disorders and infectious diseases like influenza, HIV, and tuberculosis.

Get a glance at the Point Of Care (Poc) Hiv Testing Industry report of share of various segments Request Free Sample

The POC HIV testing equipment segment was valued at USD 1575.00 million in 2018 and showed a gradual increase during the forecast period.

Regional Analysis

North America is estimated to contribute 41% to the growth of the global market during the forecast period.

Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

For more insights on the market share of various regions, Request Free Sample

The market in North America has experienced notable growth due to advancements in medical research, enhanced healthcare infrastructure, and heightened awareness regarding HIV/AIDS. The market caters to the US, Canada, and Mexico, with the region's well-developed healthcare system and thriving industry fueling demand for HIV treatment